MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5410
-0.0040
-0.73%
Opening 14:10 06/29 EDT
OPEN
0.5400
PREV CLOSE
0.5450
HIGH
0.5818
LOW
0.5301
VOLUME
137.40K
TURNOVER
45.44K
52 WEEK HIGH
3.760
52 WEEK LOW
0.3600
MARKET CAP
36.63M
P/E (TTM)
-0.4546
1D
5D
1M
3M
1Y
5Y
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
EVANSTON, Ill., June 22, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainw...
Business Wire · 06/22 11:47
BRIEF-Aptinyx - On June 9, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing - SEC Filing
reuters.com · 06/10 21:01
Expert Ratings for Aptinyx
Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:
Benzinga · 05/19 13:04
Piper Sandler Adjusts Price Target on Aptinyx to $6 From $10, Reiterates Overweight Rating
MT Newswires · 05/19 07:04
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwr...
Business Wire · 05/18 11:37
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783...
Business Wire · 05/17 11:37
Recap: Aptinyx Q1 Earnings
Aptinyx (NASDAQ:APTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 3.33%, reporting an EPS of $-0.29 versus an estimate of $-0...
Benzinga · 05/12 22:39
Aptinyx Q1 EPS $(0.29) Beats $(0.30) Estimate
Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.30) by 3.33 percent. This is a 31.82 percent decrease over losses of $(0.22) per share from the same
Benzinga · 05/12 21:12
More
No Data
Learn about the latest financial forecast of APTX. Analyze the recent business situations of Aptinyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
75.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APTX stock price target is 4.667 with a high estimate of 6.00 and a low estimate of 2.000.
High6.00
Average4.667
Low2.000
Current 0.5410
EPS
Actual
Estimate
-0.28-0.21-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 86
Institutional Holdings: 36.10M
% Owned: 53.31%
Shares Outstanding: 67.72M
TypeInstitutionsShares
Increased
15
1.41M
New
12
2.41M
Decreased
13
719.34K
Sold Out
1
1.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.92%
Pharmaceuticals & Medical Research
+0.91%
Key Executives
Chairman/Executive Director
Norbert Riedel
President/Chief Executive Officer/Director
Andrew Kidd
Chief Financial Officer
Ashish Khanna
Lead Director/Independent Director
Patrick Enright
Independent Director
Henry Gosebruch
Independent Director
Elisha Gould
Independent Director
Robert Hombach
Independent Director
Adam Koppel
Independent Director
Joan Miller
Independent Director
Gilmore O Neill
Independent Director
Rachel Sherman
No Data
No Data
About APTX
Aptinyx Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which are focused on brain and nervous system functions. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and Lewy body dementia.

Webull offers kinds of Aptinyx Inc stock information, including NASDAQ:APTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTX stock methods without spending real money on the virtual paper trading platform.